Could T-DXd outperform standard care for multiple HER2-Positive cancers? new study investigates

NCT ID NCT06973161

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal is to see if T-DXd helps patients live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab deruxtecan (T-DXd)
What this could lead to: If successful, this could provide stronger evidence that T-DXd is more effective than standard treatments for several HER2-positive cancers.
What could go wrong: This is a retrospective study using existing data, not a new trial. Results may be less reliable than a randomized controlled trial, and differences in patient groups could skew comparisons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms cervical cancer colorectal adenocarcinoma colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma ovarian cancer ovarian carcinoma pancreatic neoplasm urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER BLADDER CANCER CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER LUNG CANCER OTHER TUMORS OVARIAN CANCER PANCREATIC CANCER

Contacts and locations

Locations

Research Site

Spartanburg, South Carolina, 29303, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Vienna, Austria
Research Site

Liège, Belgium
Research Site

London, Ontario, N6A 5A5, Canada
Research Site

Olomouc, Czechia
Research Site

Copenhagen, Denmark
Research Site

Caen, France
Research Site

Lille, France
Research Site

Marseille, France
Research Site

Nice, France
Research Site

Paris, France
Research Site

Saint-Herblain, France
Research Site

Berlin, Germany
Research Site

Essen, Germany
Research Site

Frankfurt, Germany
Research Site

Heidelberg, Germany
Research Site

Würzburg, Germany
Research Site

Meldola, Italy
Research Site

Rome, Italy
Research Site

Porto, Portugal
Research Site

Barcelona, Spain
Research Site

Madrid, Spain
Research Site

Pamplona, Spain
Research Site

Valencia, Spain
Research Site

Leeds, United Kingdom
Research Site

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.